推进1型糖尿病管理:整合新疗法,技术和辅助方法
Jennifer R Snaith1,2,3, Phoom Narongkiatikhun4,5, Petter Bjornstad4,6
1Diabetes and Metabolism, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
尽管有技术,但1型糖尿病的管理仍面临挑战. 新型疗法和综合系统有望减少并发症并改善患者的幸福感.
科学领域:
- 内分泌学
- 代谢疾病
- 生物医学工程
背景情况:
- 一型糖尿病 (T1D) 需要终身胰岛素,但患者会出现血糖不良,心血管/脏疾病和痛苦等并发症.
- 传统的风险因素不足以解释T1D中血管并发症的高负担.
- 皮下胰岛素治疗可能会加剧胰岛素耐药性,炎症和内皮功能障碍,这与肥胖无关.
研究的目的:
- 探索先进技术和T1D的辅助疗法之间的协同作用.
- 解决T1D代谢功能障碍的独特生理驱动因素.
- 确定T1D管理的新疗法.
主要方法:
- 对T1D管理的新兴证据的审查.
- 探索技术创新 (多激素系统,动态监测,自动化胰岛素定位).
- 考虑使用非胰岛素辅助疗法 (营养刺激激素,胰岛素敏感剂,SGLT2抑制剂).
主要成果:
- 技术进步为改善T1D控制提供了潜力.
- 包括新药类在内的辅助疗法在治疗代谢功能障碍方面表现有前途.
- 针对T1D的组合疗法可以减轻代谢和血管并发症.
结论:
- 结合技术和新型治疗方法的协同方法对于T1D管理至关重要.
- 未来的研究应该专注于开发和测试T1D的组合疗法.
- 优化T1D治疗可以减少患者的负担和长期并发症.
更多相关视频
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Symptoms, Diagnosis, and Complications
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
